#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	16274	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2101	768.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1407	1407	C	915	C	860	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	16274	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2101	768.1	0	HET	.	.	.	G1158A	.	1158	1158	G	1381	1381	G	928	G,A	633,242	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30004	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3696	809.4	0	.	n	.	0	T695C	SNP	695	695	T	1058	1058	C	909	C	852	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30004	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3696	809.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1700	1700	A	1032	A	959	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30004	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3696	809.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2334	2334	C	940	C	879	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30004	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3696	809.4	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2960	2960	T	890	T,C,A	501,334,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30004	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3696	809.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2408	2408	A	908	A	863	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30004	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3696	809.4	0	HET	.	.	.	G2872A	.	2872	2872	G	3235	3235	G	897	G,A	619,209	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1934	folP	852	852	100.0	folP.l15.c4.ctg.1	1453	132.1	1	SNP	p	R228S	1	.	.	682	684	AGC	984	986	AGC	192;193;192	A;G;C	182;183;180	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4940	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3365	146.4	1	SNP	p	S91F	0	.	.	271	273	TCC	579	581	TCC	182;180;185	T;C;C	170;169;172	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4940	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3365	146.4	1	SNP	p	D95N	0	.	.	283	285	GAC	591	593	GAC	178;180;181	G;A;C	165;167;168	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4940	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3365	146.4	1	SNP	p	D95G	0	.	.	283	285	GAC	591	593	GAC	178;180;181	G;A;C	165;167;168	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	1656	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1230	133.7	1	SNP	p	G45D	1	.	.	133	135	GAC	417	419	GAC	186;186;190	G,T;A;C	173,1;170;179	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	844	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	996	84.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5116	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2874	177.3	1	SNP	p	D86N	0	.	.	256	258	GAC	565	567	GAC	179;180;180	G;A;C	172;169;174	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5116	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2874	177.3	1	SNP	p	S87R	0	.	.	259	261	AGT	568	570	AGT	181;180;180	A;G;T	172;174;172	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5116	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2874	177.3	1	SNP	p	S87I	0	.	.	259	261	AGT	568	570	AGT	181;180;180	A;G;T	172;174;172	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5116	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2874	177.3	1	SNP	p	S87W	0	.	.	259	261	AGT	568	570	AGT	181;180;180	A;G;T	172;174;172	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5116	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2874	177.3	1	SNP	p	S88P	0	.	.	262	264	TCC	571	573	TCC	183;185;186	TCC,TC;C;C	175,1;174;177	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4234	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2609	161.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1543	1545	GGC	222;222;224	G;G,T;C	203;201,1;209	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2465	164.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1274	1276	GCA	231;229;226	G,A;C;A	211,1;209;210	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2465	164.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1277	1279	ATC	228;229;233	A;T;C	210;214;217	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2465	164.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1289	1291	GTG	233;233;236	G;T,C;G	214;212,2;219	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2465	164.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1289	1291	GTG	233;233;236	G;T,C;G	214;212,2;219	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2465	164.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1793	1795	ACC	203;202;204	A;C;C	179;184;189	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2465	164.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1847	1849	GCG	195;194;193	G;C,G;G	172;156,1;158	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2465	164.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1847	1849	GCG	195;194;193	G;C,G;G	172;156,1;158	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2465	164.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1970	1972	GGC	138;137;137	G;G;C	127;122;127	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2465	164.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1979	1981	GGC	143;141;137	G;G;C,T	131;127;126,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2465	164.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1997	1999	CCG	122;125;124	C,G;C;G	98,4;103;99	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5902	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3134	187.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2120	porA	1146	1146	99.83	porA.l6.c17.ctg.1	1907	110.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	547	547	C	150	C	137	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	390	392	GGA	294;293;295	G;G,A;A	272;269,1;273	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	V75I	NONSYN	223	225	GTT	471	473	ATT	279;280;284	A;T;T	263;264;267	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	T89S	NONSYN	265	267	ACC	513	515	AGC	257;257;255	A;G;C	238;236;236	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	V98I	NONSYN	292	294	GTC	540	542	ATC	255;257;258	A;T;C	239;236;247	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	.	MULTIPLE	358	359	AA	605	606	CG	245;248	C;G,T	235;226,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	.	MULTIPLE	361	362	GA	608	610	CAG	252;251;251	C;A;G	233;232;236	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	N122K	NONSYN	364	366	AAC	612	614	AAA	251;251;249	A;A;A	234;238;235	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	639	641	TAT	246;247;246	T;A;T	229;231;228	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	N134E	NONSYN	400	402	AAT	648	650	GAG	252;252;251	G;A;G	235;234;235	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	V135L	NONSYN	403	405	GTG	651	653	CTT	253;258;259	C;T;T	237;241;241	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	G140K	NONSYN	418	420	GGA	666	668	AAA	263;269;267	A;A,C;A	249;251,1;252	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	K143E	NONSYN	427	429	AAA	675	677	GAA	257;256;254	G;A;A	239;239;238	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	V151A	NONSYN	451	453	GTA	699	701	GCA	267;266;271	G;C;A	248;248;254	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	T213S	NONSYN	637	639	ACA	885	887	TCA	249;251;247	T,G;C;A	237,1;239;236	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1005	1007	CAA	245;243;242	C;A;A	232;232;231	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	.	INDELS	760	761	AC	1009	1012	ATCG	236;238;237;236	A;T;C;G	224;223;228;227	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	.	INDELS	763	764	TG	1015	1018	TAGT	234;234;234;235	T;A;G;T	224;225;225;224	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1023	1025	GAT	237;236;238	G;A;T	225;226;228	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1131	1133	AGT	269;267;268	A;G;T	257;254;251	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1137	1139	GAC	276;276;278	G;A;C	259;258;261	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1140	1142	TAC	283;282;285	T;A;C	265;263;265	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	1	SNP	p	G120K	1	.	.	358	360	AAG	605	607	CGG	245;248;249	C;G,T;G	235;226,1;233	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	1	SNP	p	A121D	1	.	.	361	363	GAC	608	611	CGC	252;251;250	C;G;C	233;236;235	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3240	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1424	225.1	1	SNP	p	D121N	0	.	.	361	363	GAC	608	611	CGC	252;251;250	C;G;C	233;236;235	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12316	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4844	253.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2032	2034	AAT	227;223;220	A,C;A;T	213,2;212;208	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1280	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1232	103.5	1	SNP	p	V57M	1	.	.	169	171	ATG	646	648	ATG	270;272;268	A;T;G	258;259;257	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
